Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients

J Mol Med (Berl). 1995 May;73(5):249-54. doi: 10.1007/BF00189925.

Abstract

The behavior of hepatitis C virus (HCV) infection with regards to type and number of HCV genotypes (tested with genotype-specific nested polymerase chain reaction) was evaluated in 60 patients with anti-HCV-positive chronic active hepatitis without cirrhosis [17 untreated and 43 subjects undergoing single or repeat courses of interferon (IFN) therapy] during a mean follow-up period of 76 +/- 18 months. In untreated patients (2 genotype I, 6 genotype II, 9 mixed infections) 4 out of 9 mixed infections selected for genotype II at the end of follow-up. Of the 43 treated patients 10 were long-term responders with histological remission, 6 were short-term responders, and 22 did not respond. Fifteen of the latter patients received another course of IFN therapy, and only 3 patients responded. Eight of the 10 responders had infection with a single genotype (4 gt I, 3 gt II, 3 gt III). After IFN therapy, all but 2 patients cleared the HCV infection. The responders to the second IFN course (1 gt I, 1 gt II, 1 gt III) remained viremic. Of the short-term responders, 2/6 patients had genotype II and 4 had a mixed infection (3 gt II +/- I and 1 gt II +/- III); gt III became prevalent in the latter in all but one patient. Of the nonresponders 18/24 had more than one genotype, 5 were genotype II at baseline and one had genotype I. At the end of the follow-up period 15/18 with mixed infection had selected for gt II (P < 0.01 vs. untreated patient).(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Evaluation Studies as Topic
  • Female
  • Follow-Up Studies
  • Genotype
  • Hepacivirus / classification
  • Hepacivirus / genetics*
  • Hepacivirus / pathogenicity*
  • Hepatitis Antibodies / blood
  • Hepatitis C / therapy*
  • Hepatitis C / virology
  • Hepatitis C Antibodies
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Liver / pathology
  • Liver Cirrhosis / diagnosis
  • Male
  • Middle Aged
  • RNA, Viral / genetics
  • Recombinant Proteins
  • Selection, Genetic*
  • Time Factors

Substances

  • Hepatitis Antibodies
  • Hepatitis C Antibodies
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins